

Jeffrey Seow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7526794/jeffrey-seow-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

2,148
citations

17
h-index

46
g-index

47
ext. papers

3,341
ext. citations

13.9
avg, IF

4.68
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 36 | Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.. <i>MBio</i> , 2022 , e0379821 | 7.8 | 4 |
| 35 | Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies.. <i>MBio</i> , 2022 , e0265021 | 7.8 | 1 |
| 34 | ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.. <i>Cell Reports</i> , 2022 , 110757 | 10.6 | 0 |
| 33 | Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients. <i>Blood</i> , 2021 , 138, 3920-3920 | 2.2 | |
| 32 | Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021 , 6, 1433-1442 | 26.6 | 32 |
| 31 | The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate. <i>Nature Immunology</i> , 2021 , 22, 1490-1502 | 19.1 | 11 |
| 30 | Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. <i>Cancer Cell</i> , 2021 , 39, 1445-1447 | 24.3 | 8 |
| 29 | Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2. <i>Vaccine</i> , 2021 , 39, 1746-1757 | 4.1 | 0 |
| 28 | The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021 , 34, 108890 | 10.6 | 113 |
| 27 | SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021 , 7, | 14.3 | 46 |
| 26 | Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , 2021 , 16, e0249791 | 3.7 | 3 |
| 25 | Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. <i>Lancet Oncology, The</i> , 2021 , 22, 765-778 | 21.7 | 240 |
| 24 | Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , 2021 , 35, 3573-3577 | 10.7 | 26 |
| 23 | Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 194, 999-1006 | 4.5 | 24 |
| 22 | Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021 , 54, 1276-1289.e6 | 32.3 | 60 |
| 21 | Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections 2021 , | | 5 |
| 20 | SARS-CoV-2 recruits a haem metabolite to evade antibody immunity 2021 , | | 8 |

| | | | |
|----|---|------|-----|
| 19 | Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike 2021 , | | 13 |
| 18 | Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , 2020 , 81, 931-936 | 18.9 | 32 |
| 17 | Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. <i>ELife</i> , 2020 , 9, | 8.9 | 8 |
| 16 | Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020 , 5, 1598-1607 | 26.6 | 667 |
| 15 | Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020 , 16, e1008817 | 7.6 | 72 |
| 14 | A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nature Medicine</i> , 2020 , 26, 1623-1635 | 50.5 | 423 |
| 13 | Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. <i>Nature Medicine</i> , 2020 , 26, 1701-1707 | 50.5 | 170 |
| 12 | A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 25057-25067 | 11.5 | 25 |
| 11 | Disordered epitopes as peptide vaccines. <i>Peptide Science</i> , 2018 , 110, e24067 | 3 | 12 |
| 10 | Transient antibody-antigen interactions mediate the strain-specific recognition of a conserved malaria epitope. <i>Communications Biology</i> , 2018 , 1, 58 | 6.7 | 5 |
| 9 | Lipid interactions modulate the structural and antigenic properties of the C-terminal domain of the malaria antigen merozoite surface protein 2. <i>FEBS Journal</i> , 2017 , 284, 2649-2662 | 5.7 | 5 |
| 8 | Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate. <i>Scientific Reports</i> , 2015 , 5, 10103 | 4.9 | 17 |
| 7 | Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19 | | 1 |
| 6 | Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service | | 2 |
| 5 | Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings | | 10 |
| 4 | A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis | | 25 |
| 3 | Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines | | 27 |
| 2 | The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate | | 1 |

1

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

1